Australia · Delayed Price · Currency is AUD SomnoMed Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 13% to AUD 60.7 million with EBITDA up 35% and stable gross margins. Europe and North America drove growth, while APAC softened. Guidance for FY 2026 is reaffirmed, with continued investment in manufacturing, R&D, and innovation, notably RestAssure.
Fiscal Year 2025
-
FY2025 delivered 22% revenue growth to $111.5 million, a dramatic EBITDA turnaround, and positive cash flow, driven by operational improvements and strong regional performance. FDA clearance for Rest Assure and expanded manufacturing set the stage for continued growth in FY2026.
-
Revenue grew 19% to AUD 53.7 million in H1 FY2025, with EBITDA improving to AUD 5.8 million and all regions achieving double-digit growth. Upgraded FY2025 guidance projects AUD 105 million revenue and AUD 7–9 million EBITDA, supported by operational efficiencies and a strengthened balance sheet.
Fiscal Year 2024
-
Revenue grew 9.6% to AUD 91.7 million in FY 2024, with EBITDA at AUD 0.6 million amid capacity constraints and margin pressure. FY 2025 guidance targets over 9% revenue growth and EBITDA above AUD 5 million, supported by manufacturing investments and strong early trading.